FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Glenmark Life Sciences IPO and Tatva Chintan Pharma IPO.
Glenmark Life Sciences IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Tatva Chintan Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Glenmark Life Sciences IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | Bofa Securities India Limited Bob Capital Markets Limited Dam Capital Advisors Ltd (Formerly Idfc Securities Ltd) Goldman Sachs (India) Securities Private Limited Kotak Mahindra Capital Company Limited SBI Capital Markets Limited |
ICICI Securities Limited Jm Financial Limited |
Registrar | Kfin Technologies Limited | Link Intime India Private Ltd |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | ||
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Glenmark Life Sciences IPO is up to ₹1,513.60 Cr whereas the issue size of the Tatva Chintan Pharma IPO is up to ₹500.00 Cr. The final issue price of Glenmark Life Sciences IPO is ₹720.00 per share and of Tatva Chintan Pharma IPO is ₹1,083.00 per share.
Glenmark Life Sciences IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Face Value | ₹2 per share | ₹10 per share |
Issue Price (Lower) | ₹695.00 per share | ₹1,073.00 per share |
Issue Price (Upper) | ₹720.00 per share | ₹1,083.00 per share |
Issue Price (Final) | ₹720.00 per share | ₹1,083.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 20 shares | 13 shares |
Fresh Issue Size | ||
Fresh Issue Size (Amount) | up to ₹1,060.00 Cr | up to ₹225.00 Cr |
OFS Issue Size | 63,00,000 shares | |
OFS Issue Size (Amount) | up to ₹453.60 Cr | up to ₹275.00 Cr |
Issue Size Total | ||
Issue Size Total (Amount) | up to ₹1,513.60 Cr | up to ₹500.00 Cr |
Glenmark Life Sciences IPO opens on Jul 27, 2021, while Tatva Chintan Pharma IPO opens on Jul 16, 2021. The closing date of Glenmark Life Sciences IPO and Tatva Chintan Pharma IPO is Jul 29, 2021, and Jul 20, 2021, respectively.
Glenmark Life Sciences IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Anchor Bid Date | ||
Issue Open | Jul 27, 2021 | Jul 16, 2021 |
Issue Close | Jul 29, 2021 | Jul 20, 2021 |
Basis Of Allotment (Tentative) | Aug 03, 2021 | Jul 26, 2021 |
Initiation of Refunds (Tentative) | Aug 04, 2021 | Jul 27, 2021 |
Credit of Share (Tentative) | Aug 05, 2021 | Jul 28, 2021 |
Listing date (Tentative) | Aug 06, 2021 | Jul 29, 2021 |
Anchor Lockin End date 1 | Sep 02, 2021 | Aug 25, 2021 |
Anchor Lockin End date 2 | Nov 01, 2021 | Oct 24, 2021 |
Glenmark Life Sciences IPO P/E ratio is , as compared to Tatva Chintan Pharma IPO P/E ratio of .
Glenmark Life Sciences IPO | Tatva Chintan Pharma IPO | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
|
|
||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 100% | 100% | ||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 82.84% | 79.17% | ||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||
ROE | ||||||||||||||||||||||||||||||||||||||||||||||
ROCE | ||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||
EPS | ||||||||||||||||||||||||||||||||||||||||||||||
RoNW |
In the Glenmark Life Sciences IPO retail investors (RII) are offered 75,43,130 shares while in Tatva Chintan Pharma IPO retail investors are offered 75,43,130 shares. Qualified institutional buyers (QIB) are offered 42,42,379 shares in Glenmark Life Sciences IPO and 9,31,966 shares in Tatva Chintan Pharma IPO.
Glenmark Life Sciences IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Anchor Investor Reserveration | ||
Market Maker Reserveration | ||
QIB | 42,42,379 shares | 9,31,966 shares |
NII | 32,32,770 shares | 6,98,975 shares |
RII | 75,43,130 shares | 16,30,941 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 1,50,18,279 shares | 32,61,882 shares |
Glenmark Life Sciences IPO subscribed 44.17x in total, whereas Tatva Chintan Pharma IPO subscribed 180.36x.
Glenmark Life Sciences IPO | Tatva Chintan Pharma IPO | |
---|---|---|
QIB (times) | 36.97x | 185.23x |
NII (times) | 122.54x | 512.22x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 14.63x | 35.35x |
Employee (times) | ||
Other (times) | ||
Total (times) | 44.17x | 180.36x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|